2023
Neuroimaging to monitor worsening of multiple sclerosis: advances supported by the grant for multiple sclerosis innovation
Oh J, Airas L, Harrison D, Järvinen E, Livingston T, Lanker S, Malik R, Okuda D, Villoslada P, de Vries H. Neuroimaging to monitor worsening of multiple sclerosis: advances supported by the grant for multiple sclerosis innovation. Frontiers In Neurology 2023, 14: 1319869. PMID: 38107636, PMCID: PMC10722910, DOI: 10.3389/fneur.2023.1319869.Peer-Reviewed Original ResearchMultiple sclerosisClinical trialsMonitoring of MSMagnetic resonance imagingPositron emission tomographyDisability worseningKey unmetCentral pathologyEarly pathologyTreatment responseNew therapiesOcular imagingUnmet needResonance imagingEmission tomographyDisease pathologyNew therapeuticsPathologyNeuroimaging measuresTrialsLongitudinal studySclerosisClinicWorseningBiomarkers
2022
Phase 3 REMODEL I/II Trials: Effectiveness, Safety, and Tolerability of Remibrutinib in Patients with Relapsing Multiple Sclerosis (P7-4.003)
Wiendl H, Airas L, Chitnis T, Williams M, Nakahara J, Bermel R, Mann A, Ziehn M, Bhatt A, Hunter B, Zhang Y, Karan R, Willi R, Kieseier B, Montalban X. Phase 3 REMODEL I/II Trials: Effectiveness, Safety, and Tolerability of Remibrutinib in Patients with Relapsing Multiple Sclerosis (P7-4.003). Neurology 2022, 98 DOI: 10.1212/wnl.98.18_supplement.2562.Peer-Reviewed Original Research
2019
Serum GFAP Associates with Neurofilament Light and Disease Severity in Late Multiple Sclerosis (P5.2-017)
Airas L, Hoegel H, Rissanen E, Matilainen M, Nylund M, Kuhle J. Serum GFAP Associates with Neurofilament Light and Disease Severity in Late Multiple Sclerosis (P5.2-017). Neurology 2019, 92 DOI: 10.1212/wnl.92.15_supplement.p5.2-017.Peer-Reviewed Original Research
2018
Natalizumab Treatment of Multiple Sclerosis Leads to Diminished Microglial Activation in the Normal Appearing White Matter (P3.390)
Airas L, Sucksdorff M, Tuisku J, Rissanen E. Natalizumab Treatment of Multiple Sclerosis Leads to Diminished Microglial Activation in the Normal Appearing White Matter (P3.390). Neurology 2018, 90 DOI: 10.1212/wnl.90.15_supplement.p3.390.Peer-Reviewed Original Research
2014
In Vivo PET Imaging of Activated Microglial Cells Can Be Used to Differentiate Between Inactive and Active Chronic Lesions in Progressive Multiple Sclerosis (S44.003)
Airas L, Rissanen E, Tuisku J, Dickens A, Anthony D, Rinne J. In Vivo PET Imaging of Activated Microglial Cells Can Be Used to Differentiate Between Inactive and Active Chronic Lesions in Progressive Multiple Sclerosis (S44.003). Neurology 2014, 82 DOI: 10.1212/wnl.82.10_supplement.s44.003.Peer-Reviewed Original Research
2013
In Vivo micro-PET Imaging Demonstrates Diminished Microglial Activation after FTY720 Treatment in an Animal Model of Multiple Sclerosis (P05.151)
Airas L, Dickens A, Haaparanta-Solin M, Anthony D, Rinne J. In Vivo micro-PET Imaging Demonstrates Diminished Microglial Activation after FTY720 Treatment in an Animal Model of Multiple Sclerosis (P05.151). Neurology 2013, 80 DOI: 10.1212/wnl.80.7_supplement.p05.151.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply